Anupam Rasayan India Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/07p1tud8geriqg85z9oagunq.pdf

Key Takeaways


The Bliss GVS Acquisition: Rationale, Margins & Synergies

Thakkar: “I think what we can say is that the active Bliss, yes, we believe that 22%-24% EBITDA margin, which we have said is an average consolidated EBITDA margin for Anupam as well, on a consolidated basis. I think that is the number that we should be looking for.”

Standalone Performance & the Margin Story

Thakkar: “Tanya, yes, we have done better on the margins, but it is also to do with the product portfolio and the products that we have sold in this quarter versus the other quarters. I would urge to caution and continue to guide at the numbers that we have been guiding.”

New Business Wins & the Order Book

Thakkar: “In a matter of just four months' time from start to now, we have been able to convert them into a six-year long-term contract, which is something which I think is very high reflective of our capabilities, that you can get a product approved in three months' time from inquiry and get a contract of six years.”

Platform Strategy & the Cyclicality Play

Thakkar: “If you look at from across, so if you look at the whole strategy here, across chemistries, across geographies, like U.S., Europe, Japan, India, and Africa, across end markets like pharma, polymer, agro, and Performance Materials like your products going into EV and semiconductor industry, across right from a very basic raw material like HF, KF for a nitrobenzene to AI or an API or a formulation or a polymer, is something which is very unique that we are building.”

Cash Flow, Working Capital & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated H2 FY27 revenue₹2,400–₹2,500 crores, implying ~₹4,800–₹5,000 crores annualized run rateH2 FY27
Organic growth from H2 run rate20–25 percentage pointsNear-term three-to-five-year period
Standalone EBITDA margin24–26% (despite current 34%, management urges reversion to this range)Sustained basis
Bliss GVS steady-state EBITDA margin22–24%Sustained basis
Revenue cyclicality reductionCyclicality to decline as Pharma and Performance Materials mix growsNext four to eight quarters
Bliss synergy momentumCDMO and supply-side benefits to begin showingThree to four quarters
New metal contract: FY27 balanceAt least ₹100–₹150 croresFY27
New metal contract: run-rate rampMonthly run rate can doubleNext year to year and a half
Order book ramp-up1.8x–2x of last year’s ~₹350 crores, scaling to ~₹2,500 crores average annual numberThis year, then two to three years
Elementium contract conclusionDiscussions ongoing, expected to conclude soonNo fixed date

Key Metrics

MetricQ2 FY27
Total income₹821 cr, +11% YoY
EBITDA₹202 cr, +41% YoY
EBITDA margin~25%, vs 19.4% in Q2 FY26
Profit after tax₹65 cr, +14% YoY
PAT margin~8%
H1 FY27 total income₹1,489 cr, +21% YoY
H1 FY27 EBITDA₹377 cr, +38% YoY
H1 FY27 EBITDA margin25.5%, vs 22.2% in H1 FY26
H1 FY27 PAT₹116 cr, +10% YoY
H1 FY27 operating cash flow₹328 cr, vs ₹334 cr in full year FY26
Revenue mix: Life science specialty chemicals42% of Q2 revenue
Revenue mix: Performance Materials28% of Q2 revenue
Revenue mix: Other fluorinated products29% of Q2 revenue
Cumulative LOIs and long-term contracts~₹17,496 cr, providing multi-year visibility
H2 FY27 consolidated revenue guidance₹2,400–₹2,500 cr, implying annualized run rate of ₹4,800–₹5,000 cr
Organic growth expectation (3–5 year)20–25%
Working capital cycle (ex-Bliss GVS)271 days, improved from 276 days
Bliss GVS Pharma stake acquired50.07% equity capital
Bliss GVS revenue contribution in Q23 days only, consolidated from acquisition date of 28 Sep 2026
Bliss GVS capacity utilizationIn the 40s (percent)
Bliss GVS steady-state EBITDA margin guidance22–24%
New US specialty metal contract: expected FY27 contribution₹100–₹150 cr, supply starting November
Order book revenue in FY26~₹350 cr, expected to reach 1.8x–2x in FY27
CRISIL ESG rating"Strong" 62, up from "Adequate" 54